Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure.
It has been reported that angiotensin converting enzyme (ACE) 2, a homologue of ACE, has direct effects on cardiac function. However, the role of ACE2 in the development of human heart failure is not fully understood. We evaluated the expression of the ACE2 gene by means of real-time RT-PCR in myocardium from 14 patients with end-stage heart failure. The amount of ACE2 mRNA positively correlated with left ventricular (LV) end-diastolic diameter (r(2)=0.56, p<0.01) but did not significantly correlate with LV ejection fraction or plasma brain natriuretic peptide levels. In conclusion, our data show that the up-regulation of the ACE2 gene in the LV myocardium of patients with severe heart failure was associated with the degree of LV dilatation and may thereby constitute an important adaptive mechanism to retard the progression of adverse LV remodeling.
Ohtsuki
Masatsugu
M
Department of Cardiology, Fujita Health University Hospital, Toyoake, Japan; 21st Century COE Program, Development Center for Targeted and Minimally Invasive Diagnosis and Treatment, Fujita Health University, Toyoake, Japan.
Morimoto
Shin-Ichiro
SI
Department of Cardiology, Fujita Health University Hospital, Toyoake, Japan.
Izawa
Hideo
H
Banbuntanehotokukai Hospital, Fujita Health University, Nagoya, Japan.
Ismail
Tevfik F
TF
Charing Cross Hospital, Imperial College NHS Trust, London, UK.
Ishibashi-Ueda
Hatsue
H
Department of Pathology, National Cardiovascular Center, Osaka, Japan.
Kato
Yasuchika
Y
Department of Cardiology, Fujita Health University Hospital, Toyoake, Japan.
Horii
Taiko
T
Cardiovascular Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Isomura
Tadashi
T
Hayama Heart Center, Kanagawa, Japan.
Suma
Hisayoshi
H
The Cardiovascular Institute Hospital, Tokyo, Japan.
Nomura
Masanori
M
Banbuntanehotokukai Hospital, Fujita Health University, Nagoya, Japan.
Hishida
Hitoshi
H
Department of Cardiology, Fujita Health University Hospital, Toyoake, Japan.
Kurahashi
Hiroki
H
21st Century COE Program, Development Center for Targeted and Minimally Invasive Diagnosis and Treatment, Fujita Health University, Toyoake, Japan; Division of Molecular Genetics, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Japan.
Ozaki
Yukio
Y
Department of Cardiology, Fujita Health University Hospital, Toyoake, Japan. Electronic address: ozakiyuk@fujita-hu.ac.jp.
D000328:Adult; D000368:Aged; D000085962:Angiotensin-Converting Enzyme 2; D015415:Biomarkers / Q000378:metabolism; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D006333:Heart Failure / Q000175:diagnosis / Q000201:enzymology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000201:enzymology / Q000473:pathology; D007703:Peptidyl-Dipeptidase A / Q000096:biosynthesis*; D020257:Ventricular Remodeling / Q000502:physiology*
D015415:Biomarkers; D007703:Peptidyl-Dipeptidase A; C000705307:ACE2 protein, human; D000085962:Angiotensin-Converting Enzyme 2